OHE Publications

OHE releases a number of publications throughout the year, authored by OHE team members and/or outside experts. All are free for download as pdf files; hard copies of some publications are available upon request.

A description of the OHE publications categories.


Office of Health Economics and RAND Europe

Occasional Paper
October 2010

Research spillovers may exist when research by one organisation creates increased output for other organisations that operate in the same or another sector of the economy.  Both the mechanisms and the ultimate value of this transfer of ideas, knowledge or know-how still are not fully understood and virtually all such research on spillovers has been focused outside the UK.  Given current constraints on public, charitable and private research funding, enhancing spillovers may become an important objective in UK science and technology policy.

Garber, A.M.

September 2010

The speaker for the OHE’s 17th Annual Lecture was Dr Alan Garber, Director both of Stanford University’s Center for Health Policy and its Center for Primary Care and Outcomes Research at the School of Medicine. His remarks focused on the national health care legislation enacted in March 2010 in the US from a unique perspective – as a practicing professor of medicine, one of the world’s leading health economists, and an expert in health care policy.  His overview touched on several of the key issues raised by the new law that relate to coverage, cost, and quality.

Garau, M. and Mestre-Ferrandiz, J.

November 2009

This study compares pricing and reimbursement (P&R) policy for 43 orphan medicinal products (OMPs) across seven EU Member States: France, Germany, Italy, The Netherlands, Spain, Sweden and the UK. Examined in particular are the standards of evidence and the criteria for P&R decisions, the availability of access before full licensing approval, and requirements for studies after the drug is available on the market.

Sussex, J.

September 2009

Written while Labour Government policies still were in force, this Briefing clearly and thoroughly examines non-discretionary cost differences between public and independent providers that may have a serious impact on the effectiveness of competition.  Four key differences are identified: corporation tax, value added tax, pension costs and cost of capital.  Critical barriers to implementing the competition policy are reviewed.

Health Economics Research Group, Office of Health Economics and RAND Europe.

Consulting Report
November 2008

Understanding the nature, extent and processes involved in the return on investment in medical research has been largely neglected as an area of serious scientific study. This report is the outcome of a one-year study commissioned by the UK Academy of Medical Sciences, the UK Medical Research Council and the Wellcome Trust. Its purpose is to compare the economic benefits accruing in the UK from medical research funded in the UK, publicly or by charities only, to the cost of that research.

Dawson, D. and Mountford, L.

September 2008

In 2008, the European Commission published a proposal for a Directive on the application of patients’ rights in cross-border health care.  This followed two 1998 landmark rulings of the European Court of Justice (ECJ) that appeared to affirm the right of patients to obtain reimbursement from their own health care systems for health care that they purchased from another EU Member State, without prior authorization.